

Docket No.

221045US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Akira MORIGUCHI, et al.

SERIAL NO:

New US PCT application based on PCT/JP00/06874

GAU:

FILED:

Herewith

EXAMINER:

FOR:

NEW USE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No.

24,618

Surinder Sachar

Registration No.

34,423



Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/01)

10/088502 JOIS RECT 7000 28 MAR 2002 SHEET 1 OF 1

Form PTO 1449		U.S. DEPARTMENT O	, ,	AT'TY DOCKET NO.		SERIAL NO.			
(Modified)		PATENT AND TRADE		221045US0PCT	New US PCT application based on PCT/JP00/06874				
			– –	APPLICANT					
LIST OF	REFE	RENCES CITED BY APP	LICANT	Akira MORIGUCHI, et al.					
				FILING DATE	GROUP				
				Herewith					
			T	U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS			
	AA	5 945 432	08/31/99	Martin M. BEDNAR et al.					
	AB	5 648 351	07/15/97	John S. KELLY et al.					
	AC								
	AD	· 							
	AE								
		r	FO	REIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION		SLATION	
	<u> </u>	NOMBER				YES		NO	
	AF								
	AG								
	AH		ļ					-	
	Al		ļ						
	AJ		 						
	AK		ļ						
	AL								
	AM								
				Including Author, Title, Date, Pertinen					
·	AN⁵	Maeda MASASHI et al.: "FK506 (tacrolimus) as a potential anti-stroke agent (3): Increased therapeutic efficacy with combined treatment of FK506 and recombinant tissue plasminogen activator (rt-PA) in a rat stroke model" JAPANESE JOURNAL OF PHARMACOLOGY, vol. 82, no. Suppl. 1, page 174P 2000							
	AO •	Y. YAGITA et al.: "Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils" LIFE SCIENCES, vol. 59, no. 19, pages 1643-1650 1996							
	AP	Thomas J. TUONG et al.: "Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats" STROKE, vol. 30, no. 6, pages 1279-1285 06/99							
	AQ `	D. BOCHELEN et al.: "Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 288, no. 2, pages 653-659 02/99							
	AR,	Kim YANG-HEE et al.: "Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator" SCIENCE, vol. 284, no. 5414, pages 647-650 04/23/99							
	AS	M.M. BEDNAR et al.: "Combination tissue plasminogen activator and ticlopidine therapy in a rabbit model of acute thromboembolic research" NEUROLOGICAL RESEARCH, vol 18, no. 1, pages 45-48 02/01/96							
	AT	production"	"FK506 as an agonist to induce the inhibition of interleukin 2 TION, vol. 53, no. 5, pages 1150-1153 Additional References sheet(s) attached						
Examiner						Date Considered			
				t citation is in conformance with MPEP 60 with next communication to applicant.	09; Draw li	ne through	citation	if not in	